Shares surged 6.1% to $33.60 in pre-market as Teva Pharmaceutical delivered second-quarter results that smashed expectations on its most closely watched metric: branded drug growth. Revenue came in at $4.1 billion, down 1% year-over-year in dollar terms, dragged by falling generics sales. But the headline grabber was the branded portfolio. Teva's three flagship innovative drugs collectively grew 43% year-over-year in local currency to over $1 billion in quarterly revenue — a milestone that defied consensus expectations of roughly $843 million and eased pressure on the second half.

  • The $1 Billion Quarter Wall Street Didn't See Coming. Analysts had expected only a marginal step-up from Q1's $837 million in branded revenue to $843 million in Q2. Instead, Teva delivered over $1 billion, led by its movement-disorder treatment hitting $696 million globally, up 40%, and its migraine drug reaching $244 million, up 56%.

Management raised the full-year outlook for all three brands,

now expecting combined 2026 revenue of approximately $3.7 billion, roughly 17% growth at the midpoint. That is a meaningful beat against the prior consensus near $3.5 billion and reduces the back-half ramp investors had worried about.

  • The EPS Miss Is Real, but It's a One-Time Acquisition Cost. Teva reported a GAAP loss of $0.49 per share, with $726 million in charges tied to its Emalex acquisition — a deal to acquire a Tourette syndrome treatment. Analysts estimate that drug could generate $950 million to $1 billion in peak annual sales, but pricing risks remain. Investors are clearly looking through the write-down; the stock's reaction signals the market values pipeline optionality — meaning the potential future revenue from new drugs — over near-term earnings noise.

  • Generics Are Shrinking, and That's by Design. Global generics revenue fell 15% year-over-year in local currency, primarily because sales of a key copycat cancer drug are eroding as more competitors enter the market. Teva's biosimilars business — cheaper versions of complex biologic drugs — is on track to hit $800 million in revenue by 2027, partially offsetting the decline. The mix shift from low-margin generics toward branded drugs is the central thesis that has driven the stock up over 10% in the past week.

  • A Structural Play on Becoming a Different Company. Teva is replacing its U.S. depositary share program with a direct NYSE listing in September, a move designed to broaden its investor base and support potential inclusion in major stock indexes. Index inclusion would trigger automatic buying by passive funds. Combined with an expected ~38% four-year compound growth rate on its branded portfolio, Teva is betting it can trade like a specialty pharma company rather than a generics manufacturer weighed down by legacy debt.